Skip Nav Destination

Issue Archive

Select Decade

Select Year

Issue

Volume 134, Issue 2

July 11 2019

In this Issue

BLOOD COMMENTARIES
CLINICAL TRIALS AND OBSERVATIONS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
TRANSPLANTATION
BLOOD WORK
ERRATA

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS

Quest of biomarkers for venetoclax-treated CLL
Clinical Trials & Observations

Davide Rossi

View Articletitled, Quest of biomarkers for venetoclax-treated CLL

CLINICAL TRIALS AND OBSERVATIONS

Facing lenalidomide-refractory myeloma
Clinical Trials & Observations

Michele Cavo

View Articletitled, Facing lenalidomide-refractory myeloma

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Novel pathways of self- and cross-tolerance in monocytes

Sandra H. P. Farsky

View Articletitled, Novel pathways of self- and cross-tolerance in monocytes

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Calming the storm in HLH

Matt S. Zinter,Michelle L. Hermiston

View Articletitled, Calming the storm in HLH

Lymphoid Neoplasia

The Pandora’s box of thalidomide analogs and their substrates

Paola Neri

View Articletitled, The Pandora’s box of thalidomide analogs and their substrates

MYELOID NEOPLASIA

Deconstructing myelodysplastic syndromes

Monica del Rey Gonzalez,Christopher Y. Park

View Articletitled, Deconstructing myelodysplastic syndromes

MYELOID NEOPLASIA

Finding Neo (antigens, that is)

Johanna Olweus,Fridtjof Lund-Johansen

View Articletitled, Finding Neo (antigens, that is)

CLINICAL TRIALS AND OBSERVATIONS

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Clinical Trials & Observations

Andrew W. Roberts,Shuo Ma,Thomas J. Kipps,Steven E. Coutre,Matthew S. Davids,Barbara Eichhorst,Michael Hallek,John C. Byrd,Kathryn Humphrey,Lang Zhou,Brenda Chyla,Jacqueline Nielsen,Jalaja Potluri,Su Young Kim,Maria Verdugo,Stephan Stilgenbauer,William G. Wierda,John F. Seymour

View Articletitled, Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Supplemental data

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Clinical Trials & Observations

Joseph Mikhael,Paul Richardson,Saad Z. Usmani,Noopur Raje,William Bensinger,Chatchada Karanes,Frank Campana,Dheepak Kanagavel,Franck Dubin,Qianying Liu,Dorothée Semiond,Kenneth Anderson

View Articletitled, A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Signaling mechanisms inducing hyporesponsiveness of phagocytes during systemic inflammation

Nicole Freise,Alina Burghard,Theresa Ortkras,Niklas Daber,Achmet Imam Chasan,Saskia-L. Jauch,Olesja Fehler,Julia Hillebrand,Mosab Schakaki,Jessica Rojas,Bodo Grimbacher,Thomas Vogl,Andreas Hoffmeier,Sven Martens,Johannes Roth,Judith Austermann

View Articletitled, Signaling mechanisms inducing hyporesponsiveness of phagocytes during systemic inflammation

Supplemental data

Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis

Sabrin Albeituni,Katherine C. Verbist,Paige E. Tedrick,Heather Tillman,Jennifer Picarsic,Rachel Bassett,Kim E. Nichols

View Articletitled, Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis

Supplemental data

LYMPHOID NEOPLASIA

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs

Adam S. Sperling,Michael Burgess,Hasmik Keshishian,Jessica A. Gasser,Shruti Bhatt,Max Jan,Mikołaj Słabicki,Rob S. Sellar,Emma C. Fink,Peter G. Miller,Brian J. Liddicoat,Quinlan L. Sievers,Rohan Sharma,Dylan N. Adams,Elyse A. Olesinski,Mariateresa Fulciniti,Namrata D. Udeshi,Eric Kuhn,Anthony Letai,Nikhil C. Munshi,Steven A. Carr,Benjamin L. Ebert

View Articletitled, Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs

Supplemental data

A novel model of controlling PD-L1 expression in ALK⁺ anaplastic large cell lymphoma revealed by CRISPR screening

Jing-Ping Zhang,Zhihui Song,Hong-Bo Wang,Lang Lang,Yuan-Zhong Yang,Wenming Xiao,Daniel E. Webster,Wei Wei,Stefan K. Barta,Marshall E. Kadin,Louis M. Staudt,Masao Nakagawa,Yibin Yang

View Articletitled, A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening

Supplemental data

MYELOID NEOPLASIA

Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes

Jasper Hsu,Andreea Reilly,Brian J. Hayes,Courtnee A. Clough,Eric Q. Konnick,Beverly Torok-Storb,Suleyman Gulsuner,David Wu,Pamela S. Becker,Siobán B. Keel,Janis L. Abkowitz,Sergei Doulatov

View Articletitled, Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes

Supplemental data

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Fiorella Schischlik,Roland Jäger,Felix Rosebrock,Eva Hug,Michael Schuster,Raimund Holly,Elisabeth Fuchs,Jelena D. Milosevic Feenstra,Edith Bogner,Bettina Gisslinger,Martin Schalling,Elisa Rumi,Daniela Pietra,Gottfried Fischer,Ingrid Faé,Loan Vulliard,Jörg Menche,Torsten Haferlach,Manja Meggendorfer,Anna Stengel,Christoph Bock,Mario Cazzola,Heinz Gisslinger,Robert Kralovics

There is a Blood Commentary on this article in this issue.

View Articletitled, Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Supplemental data

TRANSPLANTATION

Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure
Brief Report

Yi-Bin Chen,Nahel Elias,Eliot Heher,Jeannine S. McCune,Kerry Collier,Shuli Li,Candice Del Rio,Areej El-Jawahri,Winfred Williams,Nina Tolkoff-Rubin,Jay A. Fishman,Steven McAfee,Bimalangshu R. Dey,Zachariah DeFilipp,Paul V. O’Donnell,A. Benedict Cosimi,David Sachs,Tatsuo Kawai,Thomas R. Spitzer

View Articletitled, Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure

BLOOD WORK

Marked lymphocytosis and atypical cells with a cleft nucleus in a 1-month-old child

Jean-Baptiste Rieu,Francois Vergez

View Articletitled, Marked lymphocytosis and atypical cells with a cleft nucleus in a 1-month-old child

Unusual histiocytes in a pleural effusion: signature of a rare disease

Christelle El Khoury,Hussein Farhat

View Articletitled, Unusual histiocytes in a pleural effusion: signature of a rare disease

ERRATA

Table of contents. Blood. 2019;133(18):iii-iv.

View Articletitled, Table of contents. Blood. 2019;133(18):iii-iv.

Ward-Caviness CK, Huffman JE, Everett K, et al. DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. Blood. 2018;132(17):1842-1850.

View Articletitled, Ward-Caviness CK, Huffman JE, Everett K, et al. DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. Blood. 2018;132(17):1842-1850.

Cover Image

Cover Image

Double-strand breaks marked by γ-H2AX (cyan) in nuclei (purple) of TP53-mutant hematopoietic progenitors. Progenitors were generated from induced pluripotent stem cells, a useful model of myelodysplastic syndromes and clonal evolution. See the article by Hsu et al on page 186.
Front Matter
Table of Contents
Back Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Mosunetuzumab next up to bat … is it a home run?

Novel CAR T cells to combat antigen escape in AML

Heme fuels venetoclax resistance in multiple myeloma

Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness

Sequential epigenetic therapy in AML

Advertisement intended for health care professionals

Table of Contents

BLOOD COMMENTARIES

Quest of biomarkers for venetoclax-treated CLL
Clinical Trials & Observations

Facing lenalidomide-refractory myeloma
Clinical Trials & Observations

Novel pathways of self- and cross-tolerance in monocytes

Calming the storm in HLH

The Pandora’s box of thalidomide analogs and their substrates

Deconstructing myelodysplastic syndromes

Finding Neo (antigens, that is)

CLINICAL TRIALS AND OBSERVATIONS

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Clinical Trials & Observations

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Signaling mechanisms inducing hyporesponsiveness of phagocytes during systemic inflammation

Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis

LYMPHOID NEOPLASIA

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs

A novel model of controlling PD-L1 expression in ALK⁺ anaplastic large cell lymphoma revealed by CRISPR screening

MYELOID NEOPLASIA

Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

TRANSPLANTATION

Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure
Brief Report

BLOOD WORK

Marked lymphocytosis and atypical cells with a cleft nucleus in a 1-month-old child

Unusual histiocytes in a pleural effusion: signature of a rare disease

ERRATA

Table of contents. Blood. 2019;133(18):iii-iv.

Ward-Caviness CK, Huffman JE, Everett K, et al. DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. Blood. 2018;132(17):1842-1850.

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

BLOOD COMMENTARIES

Quest of biomarkers for venetoclax-treated CLL Clinical Trials & Observations

Facing lenalidomide-refractory myeloma Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables Clinical Trials & Observations

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

TRANSPLANTATION

Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure Brief Report

BLOOD WORK

ERRATA

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Quest of biomarkers for venetoclax-treated CLL
Clinical Trials & Observations

Facing lenalidomide-refractory myeloma
Clinical Trials & Observations

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Clinical Trials & Observations

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Clinical Trials & Observations

Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure
Brief Report